longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

TIANYU PHARM

300702

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 78.09, within the reasonable range, cheaper than 33.8% of the time in the past 5 years, and the industry ranks 133/221, the industry Median 23.00.

78.09xP/E
¥20.32Stock price
¥0.26Earnings per share
78.09xP/E
Stock price¥20.32Earnings per share¥0.26

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
58.97x
Typical range
-72.61x–89.90x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 23.00x
020406080

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 23.00x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
002653SZHaisco
75.22x298.55%¥71.41B
603858SHBUCHANG PHARMA
64.71x--¥15.25B
300723SZApicHope
68.96x255.12%¥15.20B
002399SZHepalink
68.55x109.91%¥13.91B
300049SZFurui Co.,Ltd.
70.74x89.66%¥11.75B
603538SHMenovo
73.94x--¥8.64B
600812SHNCPC
68.68x--¥8.48B
300702SZTIANYU PHARM
78.09x121.95%¥7.07B
603229SHAusun Pharm
77.02x106.25%¥6.24B
002907SZPharscin Pharma
73.64x--¥5.46B
002728SZTY PHAR.
62.40x181.25%¥4.67B
300194SZFuan Pharmaceutical
75.99x--¥4.53B
002644SZFoci Pharmaceutical
72.81x--¥4.28B
600222SHTaloph
79.95x--¥4.21B
000919SZJINLING PHARM.
71.90x--¥4.02B
002365SZYONGAN PHARMACEUTICAL
75.15x--¥4.01B
002693SZSC Pharmaceuticals
68.77x--¥3.52B
300584SZHicin Pharmaceutical
77.42x--¥3.48B
300636SZSYNERGY
72.25x0.57%¥2.83B
002566SZYISHENG PHARM
62.14x--¥2.30B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.